MAPK3 and type 2 diabetes mellitus: Whereas T2D alone activates Erk1/2 signaling, we posit that MCU inhibition in T2D hyperactivates Erk1/2 signaling to the extent that treatment with a growth factor like PDGF has no additional effect on Erk1/2 activation, effectively inhibiting proliferation.